Latest News

Noxopharm provides update on NOX66 Clinical Trial Program
Idronoxil data provides hope to treat secondary brain cancer
NOX66 confirmed Non-Toxic. Trial Cleared for Full Enrolment
Noxopharm Mid- Year Briefing May 2017
New Corporate Presentation
St Vincents Cancer Study to Commence-NOX66 and Radiotherapy
Independent Investment Research Report May 2017
NOX makes strategic commitment to treatment of rare cancers
AFR Editorial : Innovations in Cancer Research
Noxopharm Mid Year Investor Briefings